VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
VTAE was delisted on the 24th of October, 2016.
78 hedge funds and large institutions have $138M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2016 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 16 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
3% more funds holding
Funds holding: 76 → 78 (+2)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
51% less capital invested
Capital invested by funds: $284M → $138M (-$146M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.4M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$10.1M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$5.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$8.82M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.8M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.4M |
| 4 |
PA
Perceptive Advisors
New York
|
-$3.62M |
| 5 |
Millennium Management
New York
|
-$3.61M |
VTAE Hedge Fund Activity: Q1 2016 in Review
78 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q1 2016, worth a combined $138M — down 51% from $284M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new VTAE positions and 16 closed out — a net gain of 2 holders — while 32 added to existing stakes and 19 trimmed.
The largest buyer was RA Capital Management, adding an estimated $11.4M. The largest seller was OrbiMed, exiting entirely with an estimated $8.82M sold.
- 78 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q1 2016, up from 76 in Q4 2015.
- Funds reported $138M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q1 2016, down 51% quarter-over-quarter.
- 18 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q1 2016 and 16 closed out, a net change of +2 holders.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q1 2016 was RA Capital Management, an estimated $11.4M added.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q1 2016 was OrbiMed, an estimated $8.82M sold.
Based on aggregated 13F filings for Q1 2016.